Search
Descriptor English: Nevirapine
Descriptor Spanish: Nevirapina
Descriptor Portuguese: Nevirapina
Descriptor French: Névirapine
Entry term(s): BI RG 587
BI-RG-587
BIRG587
Hemihydrate, Nevirapine
Nevirapine Hemihydrate
Viramune
Tree number(s): D03.383.725.506
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D019829
Scope note: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
Annotation:
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Reverse Transcriptase Inhibitors
Anti-HIV Agents
Cytochrome P-450 CYP3A Inducers
Registry Number: 99DK7FVK1H
CAS Type 1 Name: 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
Previous Indexing: Azepines (1991-1992)
Pyridines (1993-1997)
Public MeSH Note: 98
History Note: 98
DeCS ID: 33411
Unique ID: D019829
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1998/01/01
Date of Entry: 1997/07/22
Revision Date: 2016/05/31
Nevirapine - Preferred
Concept UI M0029429
Scope note A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
Preferred term Nevirapine
Nevirapine Hemihydrate - Narrower
Concept UI M0592535
Preferred term Nevirapine Hemihydrate
Entry term(s) Hemihydrate, Nevirapine
Viramune - Narrower
Concept UI M0373315
Preferred term Viramune
BI-RG-587 - Narrower
Concept UI M0373316
Preferred term BI-RG-587
Entry term(s) BI RG 587
BIRG587



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey